Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03477162 · ClinicalTrials.gov registry record · Early Phase 1
Metformin Pharmacology in Human Cancers: A Proof of Principle Study
A Early Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT03477162 is a Early Phase 1 study that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 18 participants.
The verdict
NCT03477162, a Early Phase 1 study, was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a presurgical (proof of principle, window of opportunity) study in patients with surgically resectable thoracic tumors to determine steady-state tissue and plasma concentrations of metformin.
Interventions
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-05-15 |
| Est. Completion | 2021-11-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03477162
The ClinicalTrials.gov registry entry for NCT03477162 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metformin is the first listed.
NCT03477162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03477162 about?
NCT03477162 is a clinical study titled "Metformin Pharmacology in Human Cancers: A Proof of Principle Study". This is a presurgical (proof of principle, window of opportunity) study in patients with surgically resectable thoracic tumors to determine steady-state tissue and plasma concentrations of metformin.
What is the current status of trial NCT03477162?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2018-05-15. Estimated completion is 2021-11-30.
What interventions are being tested in trial NCT03477162?
The interventions under investigation include: Metformin (DRUG).
Who is sponsoring clinical trial NCT03477162?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.